CTLA 4 News and Research

RSS

A novel multi-epitope vaccine targeting extracellular proteins of Chlamydia pneumoniae

Researchers designed and evaluated a multi-epitope vaccine targeting the main outer membrane protein of Chlamydia pneumoniae using immunoinformatics.

14 Sep 2023

Anti-estrogenic therapies can suppress growth of ER-negative cancers

Anti-estrogenic therapies can suppress the growth of cancer that does not express estrogen receptors; when combined with immune checkpoint inhibitor therapies, they halt tumor progression in mice models.

21 Aug 2023

Immunotherapy combination extends progression-free survival in patients with melanoma

A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to the widely used immunotherapy drugs known as PD-1 inhibitors.

17 Aug 2023

Salk scientists find new immunotherapy treatment for glioblastoma

Glioblastoma, the most common and deadly form of brain cancer, grows rapidly to invade and destroy healthy brain tissue. The tumor sends out cancerous tendrils into the brain that make surgical tumor removal extremely difficult or impossible.

11 Aug 2023

Tails on engineered T cells could help fight cancer

In a promising form of immunotherapy known as CAR T-cell (chimeric antigen receptor) therapy, the patient's T cells are engineered to better recognize and attack antigens on the surface of cancer cells.

27 Jul 2023

Tumor-derived GDF-15 suppresses immunotherapy response

Researchers evaluate the impact of tumor-derived GDF-15 on responses to anti-PD-1 immunotherapy.

26 Jul 2023

High tumor monocyte content linked to better outcomes for esophageal cancer patients

A Ludwig Cancer Research study has discovered that the presence of relatively high numbers of immune cells known as monocytes in tumors is linked to better outcomes in esophageal cancer patients treated with a combination of chemotherapy and immunotherapy, or immunochemotherapy.

10 Jul 2023

How lipid metabolites in the gut aid in regulatory T-cell differentiation

Researchers describe the Treg-cell-inducing activity of lipid extracts from the feces of specific-pathogen-free mice.

6 Jun 2023

SWOG investigators report results from DART clinical trial of immunotherapy combination for rare gynecologic cancers

Results from the S1609 DART clinical trial, which tested an immunotherapy combination of ipilimumab plus nivolumab in 53 cohorts of patients with rare cancers, are being reported for five cohorts of patients who had rare gynecologic cancers.

18 Apr 2023

Immunotherapy response in patients with advanced melanoma depends on prior treatments

Research led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to a type of immunotherapy called PD-1 checkpoint blockade in patients with advanced melanoma depended on whether or not they had previously received another immunotherapy – CTLA-4 blockade – as well as other factors.

10 Apr 2023

Phase 2 study shows safety and efficacy of new drug in men with high-risk prostate cancers

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

6 Apr 2023

Ipsilateral vaccination improves response to second dose of COVID-19 vaccine

Researchers examine whether the involvement of the ipsilateral or contralateral lymph nodes affected the immune response during sequential vaccination.

16 Mar 2023

Trial shows encouraging results for neoadjuvant dual immunotherapy and chemotherapy in patients with resectable NSCLC

In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).

16 Mar 2023

Recent therapeutic strategies for renal cell carcinoma and the effects of the tumor microenvironment on systemic therapy

Researchers explored the association between the human microbiome and improved renal cell carcinoma outcomes.

6 Feb 2023

Novel triple immunotherapy combination improves anti-tumor responses in preclinical models of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with poor prognosis and limited treatment options.

3 Jan 2023

Experimental therapy shows promise as treatment for metastatic colon cancer in preclinical models

An experimental therapy showed promise as treatment for an aggressively spreading type of colorectal cancer in preclinical models, according to a new study by Weill Cornell Medicine investigators.

16 Dec 2022

Study: No significant difference in cancer risk in rheumatology patients with history of malignancy taking DMARDs

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, found no significant difference in cancer risk in patients with rheumatic disease and a history of malignancy taking biologic or targeted synthetic DMARDs compared to those treated with TNF inhibitors.

8 Nov 2022

Pioneering gene editing technique can repair faulty T cells in patients with CTLA-4 insufficiency

A fault in cells that form a key part of the immune system can be repaired with a pioneering gene editing technique, finds new research demonstrated in human cells and mice, led by UCL scientists.

27 Oct 2022

Study explores the effect of age-associated B cells on COVID-19 vaccine-induced immunity

In a new study, a team of researchers explored the effect of immune checkpoint blockade (ICB)-induced expansion of age-associated B cells (ABCs) on COVID-19 vaccine-derived humoral immunity in patients with cancer and inborn errors of immunity (IEI).

22 Sep 2022

Tumor-infiltrating lymphocytes therapy treats cancers at a large scale

A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported at the ESMO Congress 2022 from the phase 3 M14TIL trial.

12 Sep 2022